Effect of finerenone on ambulatory blood pressure in chronic kidney disease in type 2 diabetes

Finerenone in Patients With Chronic Kidney Disease and Type 2 Diabetes by Sodium–Glucose Cotransporter 2 Inhibitor Treatment: The FIDELITY Analysis

(2022) Peter Rossing et al.   DIABETES CARE

Cardiovascular Events with Finerenone in Kidney Disease and Type 2 Diabetes

(2021) Bertram Pitt et al.   NEW ENGLAND JOURNAL OF MEDICINE

Cardiovascular and kidney outcomes with finerenone in patients with type 2 diabetes and chronic kidney disease: the FIDELITY pooled analysis

(2021) Rajiv Agarwal et al.   EUROPEAN HEART JOURNAL

Steroidal and non-steroidal mineralocorticoid receptor antagonists in cardiorenal medicine

(2020) Rajiv Agarwal et al.   EUROPEAN HEART JOURNAL

Effect of Finerenone on Chronic Kidney Disease Outcomes in Type 2 Diabetes

(2020) George L. Bakris et al.   NEW ENGLAND JOURNAL OF MEDICINE

Ambulatory Blood Pressure Reduction With SGLT-2 Inhibitors: Dose-Response Meta-analysis and Comparative Evaluation With Low-Dose Hydrochlorothiazide

(2019) Panagiotis I. Georgianos et al.   DIABETES CARE

Considerable international variation exists in blood pressure control and antihypertensive prescription patterns in chronic kidney disease

(2019) Natalia Alencar de Pinho et al.   KIDNEY INTERNATIONAL

Association of Office and Ambulatory Blood Pressure With Mortality and Cardiovascular Outcomes

(2019) Wen-Yi Yang et al.   JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION

Patiromer versus placebo to enable spironolactone use in patients with resistant hypertension and chronic kidney disease (AMBER): a phase 2, randomised, double-blind, placebo-controlled trial

(2019) Rajiv Agarwal et al.   LANCET

2018 ESC/ESH Guidelines for the management of arterial hypertension

(2018) Bryan Williams et al.   EUROPEAN HEART JOURNAL

2017 ACC/AHA/AAPA/ABC/ACPM/AGS/APhA/ASH/ASPC/NMA/PCNA Guideline for the Prevention, Detection, Evaluation, and Management of High Blood Pressure in Adults: Executive Summary: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines

(2017) Paul K. Whelton et al.   HYPERTENSION

Effect of Finerenone on Albuminuria in Patients With Diabetic Nephropathy

(2015) George L. Bakris et al.   JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION

Finerenone Impedes Aldosterone-dependent Nuclear Import of the Mineralocorticoid Receptor and Prevents Genomic Recruitment of Steroid Receptor Coactivator-1

(2015) Larbi Amazit et al.   JOURNAL OF BIOLOGICAL CHEMISTRY

Safety and tolerability of the novel non-steroidal mineralocorticoid receptor antagonist BAY 94-8862 in patients with chronic heart failure and mild or moderate chronic kidney disease: a randomized, double-blind trial

(2013) Bertram Pitt et al.   EUROPEAN HEART JOURNAL

Rationale and design of ARTS: a randomized, double-blind study of BAY 94-8862 in patients with chronic heart failure and mild or moderate chronic kidney disease

(2012) Bertram Pitt et al.   EUROPEAN JOURNAL OF HEART FAILURE

Eplerenone in Patients with Systolic Heart Failure and Mild Symptoms

(2010) Faiez Zannad et al.   NEW ENGLAND JOURNAL OF MEDICINE

Daytime and Nighttime Blood Pressure as Predictors of Death and Cause-Specific Cardiovascular Events in Hypertension

(2007) Robert H. Fagard et al.   HYPERTENSION